Sir Tony Kouzarides | |
---|---|
Born | [1] | 17 January 1958
Alma mater | University of Leeds (BSc) University of Cambridge (PhD) |
Awards | Heinrich Wieland Prize (2013) Fellow of the Royal Society (2012) [2] FMedSci (2001) [3] |
Scientific career | |
Fields | Cancer Chromatin Transcription |
Institutions | University of Leeds University of Cambridge Gurdon Institute New York University Laboratory of Molecular Biology Abcam |
Thesis | A molecular analysis of transformation by human cytomegalovirus (1985) |
Doctoral advisor | Tony Minson [4] |
Website | www royalsociety |
Sir Tony Kouzarides, FMedSci, [3] FRS [2] (born 17 January 1958) is a senior group leader at the Gurdon Institute, [5] a founding non-executive director of Abcam [6] and a Professor of Cancer Biology at the University of Cambridge. [7]
Tony Kouzarides did his PhD at the University of Cambridge and his postdoctoral work at MRC Laboratory of Molecular Biology in Cambridge. After his studies, he joined NYU Medical Center in New York where he worked on the c-Fos oncoprotein and the characterization of the leucine zipper.
Tony Kouzarides is Professor of Cancer Biology at the University of Cambridge and a group leader at the Gurdon Institute, a research institution focused on epigenetic modifications and their involvement in cancer. He currently holds the following directorships: Director and Co-founder of the Milner Therapeutics Institute, director of Cambridge Gravity and director of STORM Therapeutics.
Tony is founder/director of Cambridge Gravity, an organization for the promotion of science at the University of Cambridge. He is founder, patron and ex-director of a cancer charity in Spain called Conquer Cancer (Vencer el Cancer). He is on the Scientific Advisory Board of the Institute of Cancer Research (UK) and on the Executive Board of the CRUK Cambridge Cancer Centre.
Tony is a co-founder and ex-director of Abcam plc, a publicly trading research reagents company in Cambridge, a co-founder and ex-director of Chroma Therapeutics, of a drug discovery company based in Oxford and a co-founder and current director of STORM Therapeutics, a drug discovery company based in Cambridge.
Kouzarides has been elected member of the European Molecular Biology Organization, Fellow of the British Academy of Medical Sciences (FMedSci), Fellow of the Royal Society (FRS), Fellow of the American Academy of Arts and Sciences (AAAS) and is a Cancer Research UK Gibb Fellow. He has been awarded the Wellcome Trust medal for research in biochemistry related to medicine (UK), the Tenovus Medal (UK), the Bodossaki Foundation prize in Biology (Greece), the Bijvoet Medal (Holland), the Biochemical Society Award Novartis Medal and Prize (UK) and the Heinrich Wieland Prize (Germany).
He was knighted in the 2024 King's Birthday Honours "for services to healthcare innovation and delivery". [8]
Sir Alan Roy Fersht is a British chemist at the MRC Laboratory of Molecular Biology, Cambridge, and an Emeritus Professor in the Department of Chemistry at the University of Cambridge. He was Master of Gonville and Caius College, Cambridge from 2012 to 2018. He works on protein folding, and is sometimes described as a founder of protein engineering.
Sir Gregory Paul Winter is a Nobel Prize-winning English molecular biologist best known for his work on the therapeutic use of monoclonal antibodies. His research career has been based almost entirely at the MRC Laboratory of Molecular Biology and the MRC Centre for Protein Engineering, in Cambridge, England.
Sir Thomas Leon Blundell, is a British biochemist, structural biologist, and science administrator. He was a member of the team of Dorothy Hodgkin that solved in 1969 the first structure of a protein hormone, insulin. Blundell has made contributions to the structural biology of polypeptide hormones, growth factors, receptor activation, signal transduction, and DNA double-strand break repair, subjects important in cancer, tuberculosis, and familial diseases. He has developed software for protein modelling and understanding the effects of mutations on protein function, leading to new approaches to structure-guided and Fragment-based lead discovery. In 1999 he co-founded the oncology company Astex Therapeutics, which has moved ten drugs into clinical trials. Blundell has played central roles in restructuring British research councils and, as President of the UK Science Council, in developing professionalism in the practice of science.
Richard Henderson is a British molecular biologist and biophysicist and pioneer in the field of electron microscopy of biological molecules. Henderson shared the Nobel Prize in Chemistry in 2017 with Jacques Dubochet and Joachim Frank. "Thanks to his work, we can look at individual atoms of living nature, thanks to cryo-electron microscopes we can see details without destroying samples, and for this he won the Nobel Prize in Chemistry."
Sir Christopher Martin Dobson was a British chemist, who was the John Humphrey Plummer Professor of Chemical and Structural Biology in the Department of Chemistry at the University of Cambridge, and Master of St John's College, Cambridge.
Andrea Hilary Brand is the Herchel Smith Professor of Molecular Biology and a Fellow of Jesus College, Cambridge. She heads a lab investigating nervous system development at the Gurdon Institute and the Department of Physiology, Development and Neuroscience. She developed the GAL4/UAS system with Norbert Perrimon which has been described as “a fly geneticist's Swiss army knife”.
Laurence Harris Pearl FRS FMedSci is a British biochemist and structural biologist who is currently Professor of Structural Biology in the Genome Damage and Stability Centre and was Head of the School of Life Sciences at the University of Sussex.
Ronald Alfred LaskeyFLSW is a British cell biologist and cancer researcher.
Sir Melvyn Francis Greaves is a British cancer biologist, and Professor of Cell Biology at the Institute of Cancer Research (ICR) in London. He is noted for his research into childhood leukaemia and the roles of evolution in cancer, including important discoveries in the genetics and molecular biology underpinning leukaemia.
Sir Shankar Balasubramanian is an Indian-born British chemist and Herchel Smith Professor of Medicinal Chemistry in the Department of Chemistry at the University of Cambridge, Senior Group Leader at the Cancer Research UK Cambridge Institute and Fellow of Trinity College, Cambridge. He is recognised for his contributions in the field of nucleic acids. He is scientific founder of Solexa and biomodal.
Simon Tavaré is a British researcher who is the founding Director of the Herbert and Florence Irving Institute of Cancer Dynamics at Columbia University. Prior to joining Columbia, he was Director of the Cancer Research UK Cambridge Institute, Professor of Cancer Research at the Department of Oncology and Professor in the Department of Applied Mathematics and Theoretical Physics (DAMTP) at the University of Cambridge.
Richard Nelson Perham, FRS, FMedSci, FRSA, was Professor of biochemistry at the University of Cambridge, and Master of St John's College, Cambridge 2004–07. He was also editor-in-chief of FEBS Journal from 1998 to 2013.
Sir Stephen Philip Jackson, FRS, FMedSci is the Frederick James Quick Professor of Biology. He is a senior group leader at the Cancer Research UK Cambridge Institute and associate group leader at the Gurdon Institute, University of Cambridge.
Sir James Cuthbert Smith is an Emeritus Scientist at the Francis Crick Institute, Honorary Fellow of Christ's College, Cambridge and President of the Council at the Zoological Society of London.
Sir Hugh Reginald Brentnall Pelham, is a cell biologist who has contributed to our understanding of the body's response to rises in temperature through the synthesis of heat shock proteins. He served as director of the Medical Research Council (MRC) Laboratory of Molecular Biology (LMB) between 2006 and 2018.
Jonathon Noë Joseph Pines is Head of the Cancer Biology Division at the Institute of Cancer Research in London. He was formerly a senior group leader at the Gurdon Institute at the University of Cambridge.
Gregory James Hannon is a professor of molecular cancer biology and director of the Cancer Research UK Cambridge Institute at the University of Cambridge. He is a Fellow of Trinity College, Cambridge while also serving as a director of cancer genomics at the New York Genome Center and an adjunct professor at Cold Spring Harbor Laboratory.
Robert Charles Swanton is a British physician scientist specialising in oncology and cancer research. Swanton is a senior group leader at London's Francis Crick Institute, Royal Society Napier Professor in Cancer and thoracic medical oncologist at University College London and University College London Hospitals, co-director of the Cancer Research UK (CRUK) Lung Cancer Centre of Excellence, and Chief Clinician of Cancer Research UK.
The Department of Genetics is a department of the University of Cambridge that conducts research and teaching in genetics.
Fiona Hamilton Marshall is a British pharmacologist, biotech-founder and President of Biomedical Research at Novartis. She founded and previously served as Chief Scientific Officer at Heptares Therapeutics, which was acquired by the Japanese biopharmaceutical company Sosei, where she served as Vice President. She was elected Fellow of the Academy of Medical Sciences in 2016 and the Royal Society in 2021.